Form 4: Arbutus Biopharma CFO Granted Stock Options

Tuan Nguyen, CFO of Arbutus Biopharma, was granted stock options for 750,000 common shares on March 31, 2025, vesting over four years.

Summary

• Tuan Nguyen, the Chief Financial Officer of Arbutus Biopharma Corp, was granted stock options on March 31, 2025.
• The options grant covers 750,000 common shares of Arbutus Biopharma.
• The exercise price of the options is $3.50 per share, reflecting the closing price on the grant date.
• The options vest over a four-year period, starting with 25% vesting on the first anniversary of the grant date.
• The remaining 75% of the options vest in substantially equal monthly installments over the subsequent three years, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of management interests. It's a neutral-positive signal.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biopharmaceutical industry to attract and retain key executives, aligning their interests with the long-term success of the company. This grant is typical for a CFO role in a company of Arbutus Biopharma's size and stage.

Comparison to Industry Standards

• Stock option grants for CFOs in similar-sized biotech companies typically range from 0.1% to 0.5% of outstanding shares.
• Vesting schedules of four years with a one-year cliff are standard practice in the industry, similar to companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals.
• The exercise price being set at the closing market price on the grant date is also a common industry practice.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Arbutus Biopharma, CFO, Tuan Nguyen, ABUS, equity compensation, Form 4